BIOLOGICAL CONTAINMENT OF LIVE BACTERIAL VACCINES

Information

  • Research Project
  • 2075672
  • ApplicationId
    2075672
  • Core Project Number
    R41AI038599
  • Full Project Number
    1R41AI038599-01
  • Serial Number
    38599
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1995 - 30 years ago
  • Project End Date
    8/31/1996 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1995 - 30 years ago
  • Budget End Date
    8/31/1996 - 29 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/28/1995 - 30 years ago
Organizations

BIOLOGICAL CONTAINMENT OF LIVE BACTERIAL VACCINES

DESCRIPTION (Adapted from Applicant's Abstract): "Our long-term goals are to develop recombinant avirulent Salmonella vaccines for oral administration, protecting humans against bacterial, viral mycotic and parasitic pathogens. This delivery system is being developed for synthesis of gamete-specific antigens, to block fertilization, and tumor antigens, to halt cancers. Augmentation and/or modulation of the immune response to foreign antigens delivered by Salmonella is being accomplished by constructing strains that also express genes for cytokines. Immunization with Salmonella vaccines introduces the potential for fecal shedding of the bacteria into the environment, possibly leading to immunization of unintended individuals. The objective of the Phase I study is to design, construct and evaluate biological containment strategies so that live vaccine strains are unable to survive and proliferate in the environment. The objectives during the Phase II study will be to construct and assess additional biological containment strategies to reinforce the primary containment strategies. These vaccine constructs will be fully evaluated for the induction of protective immunity following vaccination of animals, including human volunteers, and for their survival in various environments likely to be encountered in nature. Recombinant avirulent S. typhimurium strains will be tested in mice and recombinant avirulent S. typhi and S. paratyphi strains evaluated in human volunteers."

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R41
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    MEGAN HEALTH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ST. LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    63110
  • Organization District
    UNITED STATES